Therapeutic regimen for hypertension
Inventors
Snyder, Eric • Sprissler, Ryan • Snyder, Scott C.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10590485-B2
Publication Date
2020-03-17
Expiration Date
Abstract
The invention relates to improved methods, devices, and kits for identifying and implementing an appropriate treatment regimen for subjects suffering from hypertension.
Core Innovation
The invention provides a method for treating an individual patient having hypertension by administering a first line therapy antihypertensive drug selected from diuretic, vasodilator, or beta blocker drug classes. The method is genotype-directed and requires determining a patient’s genotype and corresponding peptide sequences for polymorphic nucleotide and polypeptide sequences and named receptor and peptide position variants.
A central feature is that the administering step is refined into procedure a, b, c, d, e, or f, each linking a specific drug class to defined homozygous or non-homozygous or heterozygous genotype conditions across multiple rs loci and amino-acid positions. The conditions explicitly reference ADRB1, ADRB2, angiotensin/threonine at position 268, angiotensin II receptor inhibitor blocker genotypes, and diuretic-relevant variants including SCNN1A threonine at 663 and SLC12A3 alanine at 264.
The disclosed context also includes nucleic-acid probe-array and genotype-detection concepts for SNP discrimination, including immobilized probes and stringent hybridization, primer-extension-based SNP discrimination, and immunoassay-based detection of protein genetic variants using antibodies and binding entities. A kit framework is also described for collecting buccal samples, extracting or stabilizing nucleic acids, and performing genotyping for multiple variants and peptides to support treatment selection and reported clinical associations between genotypes and antihypertensive response, including time to blood pressure control.
Claims Coverage
The document contains one principal independent claim defining genotype-determined first line therapy selection for hypertension, with additional independent-claim-level refinements. Across the independent claims, the inventive coverage is characterized by genotype determination for multiple polymorphic nucleotide and polypeptide sequences linked to mutually exclusive drug-class procedures a to f, and by treatment-response and treatment-timing refinements.
Genotype-determined first line antihypertensive selection for hypertension
A method for treating an individual patient having hypertension by administering a first line therapy antihypertensive drug selected from diuretic, vasodilator, and beta blocker drug classes, wherein the method determines the individual patient’s genotype and corresponding peptide sequences for multiple listed polymorphic nucleotide and polypeptide sequences and peptide position variants, and administering the drug according to one of procedures a to f defined by specific homozygous and non-homozygous or heterozygous genotype conditions.
Improved blood pressure response criterion for drug selection
Selecting an individual patient for whom the method provides an improved blood pressure response to a specified first line therapy antihypertensive drug compared with what the patient would show with a different antihypertensive drug, where the drug administered according to the first selection is different from the drug that would be administered instead.
Second drug administration after at least one month based on drug-class set
Administering a different second antihypertensive drug to the patient after at least one month of giving the first line drug, where the second drug is a diuretic, beta-blocker, or vasodilator.
Overall claim coverage centers on genotype-directed antihypertensive selection using specified polymorphic nucleotide and polypeptide sequences and amino-acid position variants, with the drug choice further constrained into specific mutually exclusive procedures and supported by treatment-response and treatment-extension refinements.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?